149 related articles for article (PubMed ID: 12659615)
1. Clinical trial response and dropout rates with olanzapine versus risperidone.
Santarlasci B; Messori A
Ann Pharmacother; 2003 Apr; 37(4):556-63. PubMed ID: 12659615
[TBL] [Abstract][Full Text] [Related]
2. Meta-analysis comparing newer antipsychotic drugs for the treatment of schizophrenia: evaluating the indirect approach.
Sauriol L; Laporta M; Edwardes MD; Deslandes M; Ricard N; Suissa S
Clin Ther; 2001 Jun; 23(6):942-56. PubMed ID: 11440294
[TBL] [Abstract][Full Text] [Related]
3. A randomized double-blind study of risperidone and olanzapine in the treatment of schizophrenia or schizoaffective disorder.
Conley RR; Mahmoud R
Am J Psychiatry; 2001 May; 158(5):765-74. PubMed ID: 11329400
[TBL] [Abstract][Full Text] [Related]
4. Differential rates of treatment discontinuation in clinical trials as a measure of treatment effectiveness for olanzapine and comparator atypical antipsychotics for schizophrenia.
Kinon BJ; Liu-Seifert H; Adams DH; Citrome L
J Clin Psychopharmacol; 2006 Dec; 26(6):632-7. PubMed ID: 17110821
[TBL] [Abstract][Full Text] [Related]
5. The effects of risperidone and olanzapine on the indications for clozapine.
Ganguli R; Brar JS
Psychopharmacol Bull; 1998; 34(1):83-7. PubMed ID: 9564203
[TBL] [Abstract][Full Text] [Related]
6. Comments on "Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders" by Tran and Associates.
Kasper S; Küfferle B
J Clin Psychopharmacol; 1998 Aug; 18(4):353-6. PubMed ID: 9690709
[No Abstract] [Full Text] [Related]
7. Obsessive-compulsive symptoms during treatment with olanzapine and risperidone: a prospective study of 113 patients with recent-onset schizophrenia or related disorders.
de Haan L; Beuk N; Hoogenboom B; Dingemans P; Linszen D
J Clin Psychiatry; 2002 Feb; 63(2):104-7. PubMed ID: 11874209
[TBL] [Abstract][Full Text] [Related]
8. Possible induction of mania and hypomania by olanzapine or risperidone: a critical review of reported cases.
Aubry JM; Simon AE; Bertschy G
J Clin Psychiatry; 2000 Sep; 61(9):649-55. PubMed ID: 11030485
[TBL] [Abstract][Full Text] [Related]
9. The effects of olanzapine, risperidone, and haloperidol on plasma prolactin levels in patients with schizophrenia.
David SR; Taylor CC; Kinon BJ; Breier A
Clin Ther; 2000 Sep; 22(9):1085-96. PubMed ID: 11048906
[TBL] [Abstract][Full Text] [Related]
10. Olanzapine and risperidone.
Love RC; Kelly DL
Am J Health Syst Pharm; 2003 Mar; 60(5):487-8; author reply 488-9. PubMed ID: 12635459
[No Abstract] [Full Text] [Related]
11. Clozapine, olanzapine, risperidone, and haloperidol in the treatment of patients with chronic schizophrenia and schizoaffective disorder.
Volavka J; Czobor P; Sheitman B; Lindenmayer JP; Citrome L; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2002 Feb; 159(2):255-62. PubMed ID: 11823268
[TBL] [Abstract][Full Text] [Related]
12. Comparison of the efficacy and acceptability of atypical antipsychotic drugs: a meta-analysis of randomized, placebo-controlled trials.
Srisurapanont M; Maneeton N
J Med Assoc Thai; 1999 Apr; 82(4):341-6. PubMed ID: 10410494
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics and cardiovascular risk in schizophrenic patients.
Bouchard RH; Demers MF; Simoneau I; Alméras N; Villeneuve J; Mottard JP; Cadrin C; Lemieux I; Després JP
J Clin Psychopharmacol; 2001 Feb; 21(1):110-1. PubMed ID: 11199934
[No Abstract] [Full Text] [Related]
14. Time to study discontinuation, relapse, and compliance with atypical or conventional antipsychotics in schizophrenia and related disorders.
Glick ID; Berg PH
Int Clin Psychopharmacol; 2002 Mar; 17(2):65-8. PubMed ID: 11890188
[TBL] [Abstract][Full Text] [Related]
15. A retrospective comparison of weight, lipid, and glucose changes between risperidone- and olanzapine-treated inpatients: metabolic outcomes after 1 year.
Meyer JM
J Clin Psychiatry; 2002 May; 63(5):425-33. PubMed ID: 12019668
[TBL] [Abstract][Full Text] [Related]
16. Changes in glucose and cholesterol levels in patients with schizophrenia treated with typical or atypical antipsychotics.
Lindenmayer JP; Czobor P; Volavka J; Citrome L; Sheitman B; McEvoy JP; Cooper TB; Chakos M; Lieberman JA
Am J Psychiatry; 2003 Feb; 160(2):290-6. PubMed ID: 12562575
[TBL] [Abstract][Full Text] [Related]
17. Benefit-risk evaluation of olanzapine, risperidone and sertindole in the treatment of schizophrenia.
Kasper S; Hale A; Azorin JM; Möller HJ
Eur Arch Psychiatry Clin Neurosci; 1999; 249 Suppl 2():II1-II14. PubMed ID: 10603070
[No Abstract] [Full Text] [Related]
18. Risperidone compared with olanzapine in a naturalistic clinical study: a cost analysis.
Taylor DM; Wright T; Libretto SE;
J Clin Psychiatry; 2003 May; 64(5):589-97. PubMed ID: 12755664
[TBL] [Abstract][Full Text] [Related]
19. An open-label randomized comparison of olanzapine versus risperidone in the treatment of childhood-onset schizophrenia.
Mozes T; Ebert T; Michal SE; Spivak B; Weizman A
J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):393-403. PubMed ID: 16958565
[TBL] [Abstract][Full Text] [Related]
20. Risperidone and olanzapine: optimal dosing for efficacy and tolerability in patients with schizophrenia.
Kasper S
Int Clin Psychopharmacol; 1998 Nov; 13(6):253-62. PubMed ID: 9861575
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
